[go: up one dir, main page]

ZA200600517B - Dosing schedule for erbB2 anticancer agents - Google Patents

Dosing schedule for erbB2 anticancer agents

Info

Publication number
ZA200600517B
ZA200600517B ZA200600517A ZA200600517A ZA200600517B ZA 200600517 B ZA200600517 B ZA 200600517B ZA 200600517 A ZA200600517 A ZA 200600517A ZA 200600517 A ZA200600517 A ZA 200600517A ZA 200600517 B ZA200600517 B ZA 200600517B
Authority
ZA
South Africa
Prior art keywords
erbb2
anticancer agents
dosing schedule
dosing
schedule
Prior art date
Application number
ZA200600517A
Other languages
English (en)
Inventor
Bhattacharya Samit Kumar
Connell Richard Damian
Moyer James Dale
Jani Jitesh Pranlal
Noe Dennis Alan
Steyn Stefanus Johannes
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200600517B publication Critical patent/ZA200600517B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200600517A 2003-08-18 2006-01-18 Dosing schedule for erbB2 anticancer agents ZA200600517B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18

Publications (1)

Publication Number Publication Date
ZA200600517B true ZA200600517B (en) 2007-02-28

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200600517A ZA200600517B (en) 2003-08-18 2006-01-18 Dosing schedule for erbB2 anticancer agents

Country Status (18)

Country Link
US (1) US20050119288A1 (fr)
EP (1) EP1658080A1 (fr)
JP (1) JP2007502807A (fr)
KR (2) KR20060037447A (fr)
CN (1) CN1838959A (fr)
AR (1) AR045268A1 (fr)
AU (1) AU2004264726A1 (fr)
BR (1) BRPI0413745A (fr)
CA (1) CA2536140A1 (fr)
CO (1) CO5670356A2 (fr)
IL (1) IL173127A0 (fr)
MX (1) MXPA06001989A (fr)
NO (1) NO20061252L (fr)
RU (1) RU2328287C2 (fr)
SG (1) SG135193A1 (fr)
TW (1) TW200522966A (fr)
WO (1) WO2005016347A1 (fr)
ZA (1) ZA200600517B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101717410B (zh) 2002-02-01 2015-04-29 阿里亚德医药股份有限公司 含磷化合物及其应用
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
NZ545459A (en) * 2003-08-14 2009-12-24 Array Biopharma Inc Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
PL1667992T3 (pl) 2003-09-19 2007-05-31 Astrazeneca Ab Pochodne chinazoliny
RS52119B (sr) 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
JP2008542354A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
JP5235662B2 (ja) * 2005-06-16 2013-07-10 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CN101360495B (zh) * 2005-11-14 2012-03-14 阿里亚德医药股份有限公司 对癌症病人给药mTOR抑制剂
DE602006009968D1 (de) 2005-11-15 2009-12-03 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
CN101484807A (zh) * 2006-03-31 2009-07-15 麻省理工学院 表达突变型egf受体的肿瘤的治疗
JP2009532497A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
JP2010509400A (ja) 2006-11-14 2010-03-25 アリアド・ファーマシューティカルズ・インコーポレイテッド 経口処方組成物
AU2008236997A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
WO2008124828A1 (fr) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Méthodes de traitement de troubles réagissant à une interruption vasculaire
WO2008124824A1 (fr) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Doses et méthodes de traitement du cancer
EP2144886A4 (fr) * 2007-04-10 2012-10-03 Myrexis Inc Méthode de traitement du mélanome
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (fr) 2007-06-08 2008-12-18 Genentech, Inc. Marqueurs d'expression de gene de resistance tumorale a un traiteme r inhibiteur her2
US8252805B2 (en) * 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (fr) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Formes de composés de lapatinib et procédés pour leur préparation
AR075896A1 (es) * 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
EP2793893A4 (fr) * 2011-11-23 2015-07-08 Intellikine Llc Régimes de traitement améliorés utilisant des inhibiteurs de mtor
EP3101115B1 (fr) 2014-01-31 2020-10-21 Toppan Printing Co., Ltd. Kit d'analyse de biomolécule et procédé d'analyse de biomolécule
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2216796C (fr) * 1995-03-30 2003-09-02 Pfizer Inc. Derives de quinazoline
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP4044839B2 (ja) * 2000-06-22 2008-02-06 ファイザー・プロダクツ・インク 異常細胞増殖を治療するための置換２環式誘導体
AU2002339687A1 (en) * 2001-12-12 2003-06-23 Pfizer Products Inc. Quinazoline derivatives for the treatement of abnormal cell growth
HRP20040530A2 (en) * 2001-12-12 2004-10-31 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
JP4611745B2 (ja) * 2002-11-20 2011-01-12 アレイ バイオファーマ、インコーポレイテッド ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン
RU2005119172A (ru) * 2002-12-18 2006-01-20 Пфайзер Продактс Инк. (Us) Производные 4-анилинхиназолина для лечения патологического роста клеток

Also Published As

Publication number Publication date
KR20080014144A (ko) 2008-02-13
TW200522966A (en) 2005-07-16
CA2536140A1 (fr) 2005-02-24
CN1838959A (zh) 2006-09-27
WO2005016347A1 (fr) 2005-02-24
SG135193A1 (en) 2007-09-28
IL173127A0 (en) 2006-06-11
US20050119288A1 (en) 2005-06-02
AR045268A1 (es) 2005-10-19
AU2004264726A1 (en) 2005-02-24
RU2006102125A (ru) 2007-09-27
BRPI0413745A (pt) 2006-10-24
EP1658080A1 (fr) 2006-05-24
CO5670356A2 (es) 2006-08-31
MXPA06001989A (es) 2006-05-17
RU2328287C2 (ru) 2008-07-10
JP2007502807A (ja) 2007-02-15
NO20061252L (no) 2006-05-16
KR20060037447A (ko) 2006-05-03

Similar Documents

Publication Publication Date Title
IL173127A0 (en) Dosing schedule for erbb2 anticancer agents
GB0211419D0 (en) Dosing system
GB2400014B (en) Harness
IL172481A0 (en) Fertilizer compositions
DE60327898D1 (en) Halter
IL174305A0 (en) 5-arylpyrimidines as anticancer agents
GB0511848D0 (en) Animal feed dispenser
GB2419078B (en) Animal restraint
GB2407471B (en) Animal harness
GB0412204D0 (en) Horse food composition
EP1645329A4 (fr) Microreacteur
GB2404183B (en) Powder dispenser
GB2421431B (en) Dosing systems
EP1709976A4 (fr) Inducteur emt
ZA200600041B (en) Fertilizer compositions
GB0325449D0 (en) Distributing components across resources
GB2418133B (en) Harness
GB0402540D0 (en) Dispensing means
GB0424130D0 (en) Scheduling software
GB0230292D0 (en) Anti-cancer agents
EP1814423A4 (fr) Harnais pour porter des charges
GB0403650D0 (en) Powder dispenser
AU156446S (en) Horse rug
GB0325332D0 (en) Feeding retainer
GB0209179D0 (en) Dosing unit